At Immuneering, we believe that collaboration drives innovation.
Our partnerships with pharmaceutical companies, academic institutions, and patient advocacy groups are central to our mission of accelerating the development of life-changing medicines for people living with cancer. By working together across industry and community, we aim to advance science, deepen patient impact, and bring forward new hope in areas of urgent need.
Regeneron Pharmaceuticals
Immuneering and Regeneron Pharmaceuticals established a clinical supply agreement to evaluate atebimetinib (IMM-1-104) in combination with Libtayo® in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer (NSCLC).
PanCAN Scientific Industry Champion
Guided by our goal to help people with cancer live longer and feel better, we are honored to support PanCAN as a Scientific & Medical Industry Champion.
